Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
Manning-Geist BL, Gordhandas SB, Giri DD, Iasonos A, Zhou Q, Girshman J, O'Cearbhaill RE, Zamarin D, Lichtman SM, Sabbatini PJ, Tew WP, Li K, McDonnell AS, Aviki EM, Chi DS, Aghajanian CA, Grisham RN. Manning-Geist BL, et al. Among authors: girshman j. Gynecol Oncol. 2022 Jan;164(1):12-17. doi: 10.1016/j.ygyno.2021.10.087. Epub 2021 Nov 8. Gynecol Oncol. 2022. PMID: 34763937 Free PMC article. Clinical Trial.
MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
Guo R, Offin M, Brannon AR, Chang J, Chow A, Delasos L, Girshman J, Wilkins O, McCarthy CG, Makhnin A, Falcon C, Scott K, Tian Y, Cecchi F, Hembrough T, Alex D, Shen R, Benayed R, Li BT, Rudin CM, Kris MG, Arcila ME, Rekhtman N, Paik P, Zehir A, Drilon A. Guo R, et al. Among authors: girshman j. Clin Cancer Res. 2021 Feb 1;27(3):799-806. doi: 10.1158/1078-0432.CCR-20-2861. Epub 2020 Nov 10. Clin Cancer Res. 2021. PMID: 33172896 Free PMC article.
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Manning-Geist BL, Kahn RM, Nemirovsky D, Girshman J, Laibangyang A, Gordhandas S, Iasonos A, Chui MH, Long Roche K, Zivanovic O, Chi DS, Aghajanian C, Grisham RN. Manning-Geist BL, et al. Among authors: girshman j. Cancer. 2023 Jul 1;129(13):2004-2012. doi: 10.1002/cncr.34753. Epub 2023 Mar 23. Cancer. 2023. PMID: 36951509
Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes.
Praiss AM, White C, Iasonos A, Selenica P, Zivanovic O, Chi DS, Abu-Rustum NR, Weigelt B, Aghajanian C, Girshman J, Park KJ, Grisham RN. Praiss AM, et al. Among authors: girshman j. Gynecol Oncol. 2024 Mar;182:32-38. doi: 10.1016/j.ygyno.2024.01.015. Epub 2024 Jan 20. Gynecol Oncol. 2024. PMID: 38246044
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.
Huicochea Castellanos S, Pagano A, Plodkowski AJ, Girshman J, Hellmann MD, Rizvi H, Flynn J, Zheng J, Capanu M, Halpenny DF, Ginsberg MS. Huicochea Castellanos S, et al. Among authors: girshman j. Lung Cancer. 2021 Nov;161:60-67. doi: 10.1016/j.lungcan.2021.08.020. Epub 2021 Sep 4. Lung Cancer. 2021. PMID: 34536733 Free PMC article.
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN; CURB Study Group. Tsai CJ, et al. Lancet. 2024 Jan 13;403(10422):171-182. doi: 10.1016/S0140-6736(23)01857-3. Epub 2023 Dec 14. Lancet. 2024. PMID: 38104577 Clinical Trial.
Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer.
Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM. Vokes NI, et al. Among authors: girshman j. JCO Precis Oncol. 2019;3:PO.19.00171. doi: 10.1200/PO.19.00171. Epub 2019 Nov 12. JCO Precis Oncol. 2019. PMID: 31832578 Free PMC article.
27 results